Tatsuro Okamoto
Overview
Explore the profile of Tatsuro Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
2475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shiraishi Y, Omasa M, Yamashita S, Hyung-Eun Y, Tanahashi M, Fukami T, et al.
Gen Thorac Cardiovasc Surg
. 2025 Feb;
PMID: 39969668
This article translates the guidelines for the treatment of empyema established by the Japanese Association of Chest Surgery in 2023 from Japanese to English. These guidelines were developed by the...
2.
Nomura K, Takada K, Kinoshita F, Muto S, Matsubara T, Kouki Y, et al.
Int J Cancer
. 2024 Nov;
156(7):1480-1491.
PMID: 39569608
The expression of programmed cell death-ligand 1 (PD-L1) and mutation in epidermal growth factor receptor (EGFR) are biomarkers used for perioperative treatment of lung adenocarcinoma. However, the clinical significance of...
3.
Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, et al.
Eur J Cancer
. 2024 Oct;
212:115052.
PMID: 39357279
Background: The effect of dual immunotherapy combined with platinum-based chemotherapy on untreated brain metastases derived from non-small cell lung cancer (NSCLC) has remained unclear. Methods: This multicenter single-arm phase 2...
4.
Koh S, Koi Y, Tajiri W, Kawasaki J, Akiyoshi S, Nakamura Y, et al.
J Med Case Rep
. 2024 Sep;
18(1):402.
PMID: 39218906
Background: Distant metastases from lung cancer are commonly found in the brain, bone, and liver. Metastases to the breast from non-mammary malignancies are extremely rare, and their clinical presentations remain...
5.
Akamine T, Takenaka T, Yano T, Okamoto T, Yamazaki K, Hamatake M, et al.
Eur J Surg Oncol
. 2024 Aug;
50(9):108374.
PMID: 39178719
Introduction: High recurrence rate following curative surgery for non-small cell lung cancer (NSCLC) presents a major clinical challenge. Understanding the site and timing of recurrence and their impact on post-recurrence...
6.
Solomon B, Dagogo-Jack I, Lee S, Boyer M, Ramalingam S, Carcereny E, et al.
JTO Clin Res Rep
. 2024 Jul;
5(7):100685.
PMID: 39034968
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in -positive or -negative advanced NSCLC, respectively. Methods: Starting...
7.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, et al.
JTO Clin Res Rep
. 2024 Apr;
5(4):100658.
PMID: 38651033
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such...
8.
Takamochi K, Haruki T, Oh S, Endo M, Funai K, Kitamura Y, et al.
J Thorac Cardiovasc Surg
. 2024 Feb;
168(2):401-410.e1.
PMID: 38348845
Objectives: This study aimed to evaluate the safety and feasibility of early chest tube removal after anatomic pulmonary resection, regardless of the drainage volume. Methods: We conducted a multicenter, randomized,...
9.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, et al.
JAMA Netw Open
. 2023 Dec;
6(12):e2347700.
PMID: 38100106
Importance: Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient. Objective: To investigate the status of biomarker testing and drug...
10.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, et al.
JTO Clin Res Rep
. 2023 Dec;
4(12):100593.
PMID: 38046378
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or...